Summary: Jesse Trekker, PhD, Business Development Director at Catalent Cell & Gene Therapy, discusses an innovative manufacturing methodology and fill/finish approaches to accelerate T-cell therapies to the commercial readiness phase.
Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.
Summary: In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies and the various solutions available for commercial scale-up of advanced therapeutics
Summary: This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using “Manufacturing by Design” Methodology
Summary: Allogeneic T-cell therapies are moving towards having breakthrough therapies available for market launch.
Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners.